U.S. markets closed

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8600-0.1400 (-4.67%)
At close: 04:00PM EDT
2.8600 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close3.0000
Bid2.7500 x 1300
Ask3.0000 x 1800
Day's Range2.8500 - 3.0100
52 Week Range2.6000 - 9.9500
Avg. Volume134,488
Market Cap81.867M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-1.7220
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LIFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • aTyr Pharma, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • GlobeNewswire

    aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

    Compositions and methods patent covers antibodies targeting NRP2 which may have therapeutic applications in the areas of cancer and inflammationSAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent covering methods for

  • GlobeNewswire

    aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

    Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. EFZO-FIT™ builds on positive results from Phase 1b/2a study which demonstrated dose dependent improvements across steroid reduction, lung function and symptom control endpoints. SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the di

  • GlobeNewswire

    Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing

    NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accep